Article in Molecular cancer research : MCR, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.
0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
2 · The registry
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
5 · Who and what money
Authors and funding
23 authors.
Amber F Gallanis *Surgical Oncology Program, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, Maryland.ORCID 0000-0003-0194-5375
Lauren A Gamble *Surgical Oncology Program, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, Maryland.ORCID 0000-0002-1389-9196
Cihan OguzIntegrated Data Sciences Section, Research Technologies Branch, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, Maryland.ORCID 0000-0002-2860-3546
Sarah G SamaranayakeSurgical Oncology Program, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, Maryland.ORCID 0000-0002-7056-5635
Noemi KedeiCollaborative Protein Technology Resource, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, Maryland.ORCID 0000-0002-6625-6119
Maria O HernandezCollaborative Protein Technology Resource, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, Maryland.ORCID 0009-0003-5114-5584
Madeline WongCenter for Cancer Research Genomics Core, Office of Science & Technology Resource, National Cancer Institute, National Institutes of Health, Bethesda, Maryland.ORCID 0000-0001-5875-1534
Desiree TilloCenter for Cancer Research Genomics Core, Office of Science & Technology Resource, National Cancer Institute, National Institutes of Health, Bethesda, Maryland.ORCID 0000-0003-3568-6148
Benjamin L GreenSurgical Oncology Program, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, Maryland.ORCID 0000-0002-5772-198X
Paul McClellandSurgical Oncology Program, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, Maryland.ORCID 0000-0002-3119-6531
Cassidy BowdenSurgical Oncology Program, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, Maryland.ORCID 0000-0002-6746-6142
Irene GulloDepartment of Pathology, Centro Hospitalar Universitário São João, Porto, Portugal.ORCID 0000-0003-3377-0530
Mark RaffeldMolecular Diagnostics, Laboratory of Pathology, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, Maryland.ORCID 0000-0002-4039-6957
Liqiang XiMolecular Diagnostics, Laboratory of Pathology, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, Maryland.ORCID 0000-0001-5033-7072
Michael KellyCenter for Cancer Research Single Cell Analysis Facility, Cancer Research Technology Program, Frederick National Laboratory for Cancer Research, Bethesda, Maryland.ORCID 0000-0003-0654-2778
Markku MiettinenLaboratory of Pathology, National Cancer Institute, National Institutes of Health, Bethesda, Maryland.ORCID 0000-0002-3282-8107
Martha QuezadoLaboratory of Pathology, National Cancer Institute, National Institutes of Health, Bethesda, Maryland.ORCID 0009-0004-0941-8662
Sun A KimLaboratory of Pathology, National Cancer Institute, National Institutes of Health, Bethesda, Maryland.ORCID 0000-0002-0891-2093
Andrew M BlakelySurgical Oncology Program, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, Maryland.ORCID 0000-0002-5013-3851
Justin LackIntegrated Data Sciences Section, Research Technologies Branch, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, Maryland.ORCID 0000-0003-0584-4010
Theo HellerNational Institute of Diabetes and Digestive and Kidney Diseases, National Institutes of Health, Bethesda, Maryland.ORCID 0000-0002-2643-6289
Jonathan M HernandezSurgical Oncology Program, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, Maryland.ORCID 0000-0001-7529-0557
Jeremy L DavisDivision of Surgical Oncology, University of Maryland School of Medicine, Baltimore, Maryland.ORCID 0000-0002-6334-6936
Funding
WORK ORDER 126643 B539 EXPAND IC SUITE75N91019D00024 · NIAID · LEIDOS BIOMEDICAL RESEARCH, INC. · PI BRISCOE, LYNN · 2019 to 2025
$3932.6M
Molecular Mechanisms Driving Hereditary Diffuse Gastric Cancer SyndromeZIDBC012159 · NCI · DIVISION OF BASIC SCIENCES - NCI · PI DAVIS, JEREMY · 2024 to 2024
$714k
Intramural NIH HHS ZID BC012159Intramural Research Program (IRP)NCI NIH HHS 75N91019D00024
6 · The paper itself
Abstract
Germline CDH1 loss-of-function mutations are causally linked to an increased lifetime risk of diffuse gastric cancer (DGC). Early, multifocal signet ring cell (SRC) lesions are ubiquitous among CDH1 variant carriers, yet only a subset of patients will develop advanced DGC. A multiomic analysis was performed to establish the molecular phenotype of early SRC lesions and how they differ from advanced DGC using 20 samples from human total gastrectomy specimens of germline CDH1 variant carriers. Spatial transcriptomic analysis demonstrated reduced CDH1 gene expression and increased expression of extracellular matrix remodeling in SRC lesions compared with unaffected adjacent gastric epithelium. Single-cell RNA sequencing revealed an SRC-enriched signature with markers REG1A, VIM, AQP5, PRR4, MUC6, and AGR2. Importantly, SRC lesions lacked alterations in known drivers of gastric cancer (TP53, ARID1A, and KRAS) and activation of associated signal transduction pathways. Advanced DGC demonstrated E-cadherin reexpression, somatic TP53 and ERBB3 mutations, and upregulated CTNNA1, MYC, and MET expression when compared with SRC lesions. IMPLICATIONS: The marked differences in the genomic and transcriptomic profiles of SRC lesions and advanced DGC support the consideration of SRC lesions as precancers in patients with germline CDH1 mutations.
Indexed as
Antigens, CDCadherinsCarcinoma, Signet Ring CellStomach NeoplasmsFemaleGerm-Line MutationHumansMaleMiddle AgedPhenotypeTranscriptomeAntigens, CDCadherinsCDH1 protein, human
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.
Spatial Analysis of Hereditary Diffuse Gastric Cancer Reveals Indolent Phenotype of Signet Ring Cell Precursors. · full record | OpenQuestion